Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study

被引：0
|
作者：
Patricia Pozo-Rosich
Messoud Ashina
Stewart J. Tepper
Sidsel Jensen
Line Pickering Boserup
Mette Krog Josiassen
Bjørn Sperling
机构：
[1] Headache Unit,Neurology Department
[2] Hospital Universitari Vall d’Hebron,Headache Research Group, Department of Medicine
[3] Vall d’Hebron Institute of Research,Department of Neurology, Danish Headache Center
[4] Universitat Autonoma de Barcelona,Department of Clinical Medicine
[5] Copenhagen University Hospital–Rigshospitalet,undefined
[6] University of Copenhagen,undefined
[7] New England Institute for Neurology and Headache,undefined
[8] H. Lundbeck A/S,undefined
来源：
Neurology and Therapy | 2024年 / 13卷
关键词：
Anti-CGRP; Eptinezumab; Migraine; Preventive treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：339 / 353
页数：14
相关论文
共 50 条
  • [31] Efficacy and Safety of Galcanezumab as a Preventive Treatment for Episodic Migraine in South Korean Patients: A Post-Hoc Analysis of a Phase 3 Clinical Trial
    Kim, Byung-Kun
    Cho, Soo-Jin
    Han, Jeong Hee
    Dell'Agnello, Grazia
    Panni, Tommaso
    Kim, Manho
    Oh, Kyungmi
    Moon, Heui-Soo
    Chu, Min Kyung
    JOURNAL OF CLINICAL NEUROLOGY, 2023, 19 (05): : 483 - 494
  • [32] Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine Patients with Prior Prophylactic Treatment Failure: Results from a Post-Hoc Analysis of the STRIVE Study
    Pascual, J.
    Buse, D. C.
    Starling, A. J.
    Ailani, J.
    Zhang, F.
    Wen, S.
    Bilitou, A.
    Desai, P.
    Pichard, H.
    Klatt, J.
    Mikol, D.
    HEADACHE, 2018, 58 : 179 - 180
  • [33] Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine Patients with Prior Prophylactic Treatment Failure: Results from a Post-Hoc Analysis of the STRIVE study
    Pascual, J.
    Buse, D.
    Starling, A. J.
    Ailani, J.
    Zhang, F.
    Wen, S.
    Bilitou, A.
    Desai, P.
    Picard, H.
    Klatt, J.
    Mikol, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 409 - 409
  • [34] Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies
    Ailani, J.
    Pearlman, E.
    Zhang, Q.
    Nagy, A. J.
    Schuh, K.
    Aurora, S. K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (03) : 542 - 549
  • [35] Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study
    Ostergaard, Helena Bleken
    Humphreys, Valerie
    Hengeveld, Ellen Margo
    Honore, Julie Broe
    Mach, Francois
    Visseren, Frank L. J.
    Westerink, Jan
    Yadav, Gourav
    Mosenzon, Ofri
    DIABETES OBESITY & METABOLISM, 2023, 25 (02): : 435 - 443
  • [36] Efficacy of Galcanezumab In Patients with Migraine and History of Failure to at least Three Preventive Treatment Categories: Subgroup Results from CONQUER Study
    Okonkwo, R.
    Tockhorn-Heidenreich, A.
    Stroud, C.
    Paget, M. -A.
    Matharu, M. S.
    Tassorelli, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 300 - 300
  • [37] Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
    Ashina, Messoud
    Tepper, Stewart
    Brandes, Jan Lewis
    Reuter, Uwe
    Boudreau, Guy
    Dolezil, David
    Cheng, Sunfa
    Zhang, Feng
    Lenz, Robert
    Klatt, Jan
    Mikol, Daniel D.
    CEPHALALGIA, 2018, 38 (10) : 1611 - 1621
  • [38] Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
    Goadsby, Peter J.
    Paemeleire, Koen
    Broessner, Gregor
    Brandes, Jan
    Klatt, Jan
    Zhang, Feng
    Picard, Hernan
    Lenz, Robert
    Mikol, Daniel D.
    CEPHALALGIA, 2019, 39 (07) : 817 - 826
  • [39] Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial
    Ashina, Messoud
    Lanteri-Minet, Michel
    Pozo-Rosich, Patricia
    Ettrup, Anders
    Christoffersen, Cecilie Laurberg
    Josiassen, Mette Krog
    Phul, Ravinder
    Sperling, Bjorn
    LANCET NEUROLOGY, 2022, 21 (07): : 597 - 607
  • [40] EFFICACY OF ERENUMAB IN PATIENTS WITH EPISODIC MIGRAINE WHO HAVE FAILED 2-4 PRIOR PREVENTIVE TREATMENTS: RESULTS FROM PRESPECIFIED SUBGROUP ANALYSES OF THE LIBERTY STUDY
    Reuter, U.
    Ferrari, M. D.
    Goadsby, P. J.
    Lanteri-Minet, M.
    Hours-Zesiger, P.
    Wen, S.
    Klatt, J.
    CEPHALALGIA, 2018, 38 : 88 - 89
12345